Sysmex Inostics
Bernadette Owen is a senior project and operations manager with extensive experience in the biotechnology and clinical research sectors. Currently serving as Senior Manager Projects at Sysmex Inostics since May 2022, Bernadette previously held senior project management roles at Precision For Medicine and worked as a Manufacturing Supervisor at Thermo Fisher Scientific, overseeing reagent production for various divisions. Earlier career stages include managerial positions at Intrexon Corporation and Taconic, as well as laboratory management at Charles River Laboratories. Educational qualifications include an MBA from Loyola University Maryland and a B.S. in Biology with a focus on Microbiology/Immunology from Virginia Tech.
This person is not in any offices
Sysmex Inostics
Leaders of the Global Liquid Biopsy Revolution As pioneers in blood-based cell-free tumor DNA (ctDNA) mutation detection, Sysmex Inostics has provided custom assays and CLIA-certified lab services to leading BioPharma companies over the last 10 years with the overall goal: to develop therapeutics that extend lives and provide diagnostics to monitor response to therapy, identify targetable resistance alterations, and detect minimal residual disease (MRD). SafeSEQ NGS technology can detect clinically relevant mutations in circulating tumor DNA (ctDNA) with robust detection as low as 0.03% mutant allele frequency (MAF), thus ensuring reliable molecular information for real-time therapy selection as well as monitoring of tumor response from across a broader range of genomic regions.